title: Electrooculography after photodynamic therapy.
abstract: OBJECTIVE
  To evaluate the changes in electrooculography (EOG) after photodynamic therapy (PDT).
  
  
  METHODS
  Thirty-eight eyes of 38 patients (21 males, 17 females) with choroidal neovascularization secondary to age related macular degeneration were included in this study. Standart PDT with verteporfin was performed on each patient. Serial EOG recordings were performed before, 1 week, and 1 month after PDT.
  
  
  RESULTS
  Mean age of the patients was 69.8+/-9.7 years (range 56 and 90 years). Seven days after PDT the visual acuity improved in 17 eyes, remained unchanged in 16 eyes and deteriorated in 5 eyes. One month after PDT the visual acuity findings were the same as the first week. New hemorrhages were seen in three eyes in the first week after PDT and visual acuity was decreased in those patients. No other patient complained of ocular and systemic adverse events. There was a statistically significant reduction in the Arden ratio of the EOG 1 week after PDT and the reduction persisted in the first month recordings.
  
  
  CONCLUSIONS
  The reduction in Arden ratio of EOG findings may indicate that retina pigment epithelium function could be affected after PDT.
authors.affiliation: Department of Ophthalmology, Erciyes University Medical Faculty, Kayseri, Turkey. aoner@erciyes.edu.tr
authors.forename: Ayse
authors.initials: A
authors.lastname: Oner
authors.forename: Sarper
authors.initials: S
authors.lastname: Karakucuk
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Mirza
authors.forename: Kuddusi
authors.initials: K
authors.lastname: Erkilic
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004596:Electroretinography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008268:Macular Degeneration / Q000150:complications* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012160:Retina / Q000503:physiopathology*; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin